Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Preclinical assessment of a novel compound for treating radiation-induced oral mucositis

Award Number: R43DE031464
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2022
PERIOD OF PERFORMANCE END DATE: 09/04/2024

Group Awards By:

View Award Description

Preclinical assessment of a novel compound for treating radiation-induced oral mucositis - Project Summary Inflammation and ulceration of mucosal tissue, called mucositis, is a severe side effect of many common treatments in oncology, including chemo- and radiotherapy. Mucositis development is costly to the health care system and can lead to poorer outcomes for patients. Mucositis of the mouth and esophagus, called oral mucositis, is particularly common in head and neck cancer patients receiving radiation therapy, where roughly 80% of patients develop this side effect. Treating oral mucositis remains a large clinical unmet need with no FDA approved treatments for patients with solid tumors. Using Sinopia Biosciences’ computational platform, we identified a unique target class and an associated small molecule for preventing and/or treating mucositis. The target class has an established safety profile in patients with solid tumors. In two studies with the acute radiation- induced hamster model of oral mucositis, we observed promising results that oral administration of the compound significantly decreased the duration of ulcerative mucositis and in some animals completely prevented the development of ulcers. The observed effect size was as large or larger than other compounds currently in the clinic tested in the same model. The test compound is a pan-inhibitor of several targets in the target class, each with multiple binding domains. In this Phase I proposal, we will test three additional compounds with different selectivity to these targets and domains in order to understand the pharmacology of this target class to determine the target that most contributes to mucositis amelioration. If successful, in Phase II of this proposal we will develop a novel compound selective for the most effective target. We will then characterize this new compound in the fractionated radiation model of oral mucositis and the chemotherapy-induced gastrointestinal mucositis to advance towards the clinic.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Oral Diseases and Disorders Research	000	1	5/7/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	SINOPIA BIOSCIENCES INC	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Oral Diseases and Disorders Research	000	1	8/29/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $318,284 )
2022	2022	SINOPIA BIOSCIENCES, INC.	3210 MERRYFIELD ROW	SAN DIEGO	CA	92121	SAN DIEGO	USA	Oral Diseases and Disorders Research	000	1	9/20/2022	NEW	$318,284
														Subtotal = $318,284

Grand Total All Awards = $318,284

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preclinical assessment of a novel compound for treating radiation-induced oral mucositis

Award Number: R43DE031464

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2022

PERIOD OF PERFORMANCE END DATE: 09/04/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer